VIDEO: ‘We can feel confident’ in Rebyota for recurrent C. difficile in high-risk patients

CHICAGO — In a Healio video exclusive, Glenn S. Tillotson, MSc, PhD, discusses the safety and sustained efficacy of Rebyota at 6 months for recurrent Clostridioides difficile infection in patients with immunocompromising conditions.“One thing we need to remember about this population is that they are often on antibiotics for other infections and conditions that suppress their immune responses,” Tillotson, a partner at GST Micro and consultant microbiologist, said. “The repeat courses of antibiotics that [patients] receive lead to a condition known as dysbiosis … thatRead More